#Genexine

[thealphareporter]

Obesity Pipeline Drugs 2024 | Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehrin

http://dlvr.it/TCQ6Sy

[businesspr]

Genexine seeks approval for anemia treatment in Korea

[thesunshinereporter]

Adult Growth Hormone Deficiency Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working | OPKO Health, Genexine, Ascendis Pharma

http://dlvr.it/T0K4tp

[mrunalnerkarblog]

Increasing prevalence of cancer is supporting the growth of the global recombinant human endostatin market

North America is expected to lead the global recombinant human endostatin market and this is attributed to the high prevalence of cancer in the region which is creating demand for such therapy. According to a report by the Centers for Disease Control and Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S. in 2015 and the number is expected to reach 1,735,350 in 2018. Also, an increasing number of clinical trials is again expected to foster the growth of the market.

Key players operating in the global recombinant human endostatin market include Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG.

A growing number of research & development activities to recognize potential applications of recombinant human endostatin is expected to foster the growth of the recombinant human endostatin market. Increasing demand for cancer treatment and ongoing studies to identify potential collagen are again fostering the growth of the market. According to the World Health Organization (WHO), around 18.1 million new cases of cancer were recorded in 2018, with 9.6 million deaths due to the disease. Also, the rise in the geriatric population around the globe coupled with the expanding pharmaceutical & biotechnology companies using recombinant human endostatin is further projected to foster the growth of the market.

Moreover, increasing investment in the research &development activities based on the use of recombinant technology is further anticipated to augment the growth of the market.

In January 2017, the PLA General Hospital in China has undertaken a clinical phase II study for recombinant human endostatin combination with radiotherapy for the treatment of Hepatocellular Carcinoma (HCC). The study was estimated to complete in December 2019.

A clinical trial is a rigorous medical procedure intended to test an important new medical product or procedure. The goal of such a trial is to provide evidence for or against the effectiveness, safety, and effectiveness of medical treatment. Clinical trials are conducted by healthcare companies to test drugs, medical devices, and other health products. Sometimes, healthcare companies conduct both clinical trials and consumer-based tests to determine whether a new product's benefits are worth the cost of introducing it into the marketplace. For Recombinant Human Endostatin, a biotechnology company called Generex has conducted an important clinical trial.

[blogaarti]

DNA Vaccines Market Scope, Size, Share, Trends, Forecast By 2027

A DNA vaccine is the latest technique that immunizes individuals against bacterial and viral diseases. In addition to this, it also offers protection against parasitic and fungal infections. The vaccine injects engineered DNA into the host body for cells to directly produce an antigen and trigger an immunologic response against cancer, parasites, bacteria, and viruses. Though still in development, the latest vaccination technology promises advantages such as enhanced immunity, specific targeting, and reduced risk compared to conventional vaccines. The third-generation vaccine technology is continuously improving as researchers study its application in combating HIV and certain kinds of cancer. Besides, the rise in rapid development in molecular biology and immunology is also a crucial factor driving growth across the DNA vaccines market. 

For More Industry Insights Read: https://www.fairfieldmarketresearch.com/report/dna-vaccines-market

Growing Incidence of Cancer and Infectious Diseases to Aid DNA Vaccines Market Expansion

The rising global population and growing cancer risk factors are accelerating the incidence of cancer. Inflated prevalence of cancer and other infectious diseases is concurrently elevating the demand for DNA vaccines. Numerous benefits of DNA vaccines include room temperature stability, greater efficacy, and accessible transportation. Moreover, DNA vaccines also stimulates the response of the immune system to cancer. With next-generation advancements, the DNA vaccines are set to demonstrate greater strength against such chronic diseases. An incessant rise in the number of cancer cases is expected to increase the adoption of DNA vaccines in the years to follow. This in turn will fuel the DNA vaccines market growth. 

Rising Pet Population to Create New Avenues for DNA Vaccines Market

The growing pet population has led to increase in demand for pet immunizations. Pets require immunizations, initial inspections, and neutering in the beginning. Then, the veteran intervention increases in their later years. Growing incidence of animal disease, animal hospital admission for vaccine doses, and the availability of trained veterinarians in hospitals is boosting demand for DNA vaccines. Furthermore, over the last decade, the global cattle population has also increased at a significant pace, creating tailwinds for market growth. Other factors such as nutritional and lifestyle changes are also contributing to the veterinary hospital sector's growth. Such a favourable scenario is likely to unlock the new phase of growth for the DNA vaccines market. 

North America to Emerge as a Key Regional Market Amid Surge in Prevalence of Diseases

North America is the only country to approve certain specific treatments, hence, the region' cements dominance in the DNA vaccines market. Furthermore, the rapid development in immunology and molecular biology, rise in prevalence of HIV and other diseases, and supporting government efforts are facilitating regional market expansion. The presence of key market players in the region and well-established veterinary organisational structures also play an essential role in the market growth. Against this backdrop, the DNA vaccines market in North America is likely to experience exponential growth. 

Prominent Market Players

Some of the major players in the DNA vaccines market include Genexine, VIATRIS INC. (Rottapharm Biotech), Takara Holdings (Takara Bio), GEOVAX LABS, INC, ELI-LILLY (Novartis Animal Health), Inovio Pharmaceuticals (VGX Animal Health), GeneOne Life Science, BOEHRINGER INGELHEIM GmbH (Merial), ZOETIS INC. (Fort Dodge Animal Health), and Zydus Cadila. 

For More Information Visit: https://www.fairfieldmarketresearch.com/report/dna-vaccines-market

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

[bidhuan]

BPOM Setujui Uji Klinik Fase 2/3 Vaksin Genexine dengan 1000 Relawan

BPOM Setujui Uji Klinik Fase 2/3 Vaksin Genexine dengan 1000 Relawan

Majalah Farmasetika – Badan Pengawas Obat dan Makanan (BPOM) menyetujui pelaksanaan uji klinik salah satu vaksin yang telah terdaftar dalam WHO Landscape adalah Vaksin COVID-19 GX-19N atau disebut juga dengan Vaksin Genexine. Vaksin GX-19N ini merupakan vaksin COVID-19 dengan platform DNA pertama yang dikembangkan oleh Genexine Korea. Industri farmasi di Indonesia, yaitu PT. Kalbe Farma akan…

[cyberhideoutflower]

View the most recent  Genexine annual financial report information including stock and share prices, market share, sales growth & profit margins.

[publictremarks]

@trademarktrader: CERVICURA new trademark application by Genexine, Inc. #CERVICURA $RZLT $RZLTD

CERVICURA new trademark application by Genexine, Inc. https://t.co/dScMHefqQZ #CERVICURA $RZLT $RZLTD pic.twitter.com/NS1GqPPZ9n

— trademark trader (@trademarktrader) January 29, 2022

from https://twitter.com/trademarktrader/status/1487369984464470016

[research-blogs]

Human Growth Hormone Market Size, Share & Growth Analysis And Regional Forecast, 2020-2027

The global human growth hormone market size is expected to reach a value of USD 8.5 billion by 2027, registering a CAGR of 8.2% over the forecast period, according to a new report by Grand View Research, Inc. Introduction of novel therapies, increasing R&D activities, and the rising awareness for the diagnosis and treatment of growth hormone (GH) disorders are expected to drive the market over the forecast period.

Key players operating in the market are involved in extensive R&D activities for the development of novel GH therapies to strengthen their position in the market. For instance, in October 2019, VISEN Pharmaceuticals, a joint venture of Denmark-based Ascendis Pharma A/S, received approval from the China National Drug Administration (NMPA) for its new drug (IND) application to start Phase III clinical study of TransCon hGH. Furthermore, two South Korean companies, Genexine Inc. and Handok Inc. are conducting a Phase II clinical trial study on GX-H9, a recombinant human GH for the treatment of adult and pediatric GH deficiency.

Furthermore, an increase in the number of regulatory approvals and the launch of novel HGH therapies are expected to fuel the market over the forecast period. For instance, in January 2018, Ferring Pharmaceuticals Inc., a Switzerland-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for its new recombinant HGH, Zomacton (somatropin), indicated for the treatment of adult patients with GH deficiency.

Various government and private organizations have been undertaking initiatives and programs to spread awareness about GH deficiency and facilitate timely diagnosis and treatment. Nonprofit organizations such as the Human Growth Foundation are engaged in providing research support and spreading awareness about GH deficiency and its treatment. Such initiatives are expected to drive the demand for hGH treatment therapies.

View detailed insights @ https://bit.ly/3CSwJ15

Human Growth Hormone Market Report Highlights

· GH deficiency was the largest application segment in 2019 owing to an increase in regulatory approvals and the launch of novel therapies

· Rising awareness about GH deficiency, coupled with increasing hospital visits for its treatment, is expected to drive the hospital pharmacy distribution channel segment

· North America dominated the human growth hormone market with the largest share in 2019. This is attributed to favorable reimbursement scenario, high awareness, and the presence of major players in the region

· Asia Pacific is projected to witness a lucrative CAGR over the forecast period owing to increasing penetration of key players with their new growth hormone therapies

· The key players include Novo Nordisk A/S; Pfizer Inc.; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc. (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries, Ltd; and Ipsen.

Get Sample PDF Copy @ https://bit.ly/3ifKcIB

[ramshariraut]

Latest Research Report On Cancer Angiogenesis Inhibitors  Market 2021

Global Cancer Angiogenesis Inhibitors  Market, Geography (North America (United States, Canada and Mexico), South America (China, Japan, Korea, India and Southeast Asia), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Middle East and Africa (Saudi Arabia, Egypt, Nigeria and South Africa)) Industry Trends 2021-2028

<strong>Market overview</strong> The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report on Cancer Angiogenesis Inhibitors  . All these factors would help marketers to take strategic steps in order to strengthen their positions and expand their shares in the international market. The market overview segment of the report explores the market dynamics such as drivers, restraints, and current opportunities that have a strong effect on the international body sensor market and could affect the market in the near future. A market-making analysis has been provided in the market overview section in order to explain the level of competition in the market across different geographies.

<strong> Request a sample Report of Cancer Angiogenesis Inhibitors  Market @ <a href=https://www.statistifymarketresearch.com/reports/cancer-angiogenesis-inhibitors-market/sample-request-81109>https://www.statistifymarketresearch.com/reports/cancer-angiogenesis-inhibitors-market/sample-request-81109</a></strong>

<strong>Methodology</strong> Experts and industry specialists play a significant role in creating statistical tools and research models, which are used to examine data and reach an accurate graph with highly informative research results which can be later used to make really important decisions related to the business. Data sources come from a large number of research studies and our in-house datasheet. Also, the report uses the top-down approach to report. This report on Cancer Angiogenesis Inhibitors   the numbers for each division and attests them to the bottom-up approach. All capable factors affecting the markets included in this research study are evaluated, elaborated, and examined through basic research and investigated to obtain quantitative and qualitative data. Structural databases such as D&B Hoover and Bloomberg are used which helps to recognize the competitive situation of top market players along with profile details. This data is merged and combined with detailed inputs and analysis from Statistify market research and revealed in this report.

<strong>Regional Analysis</strong> The survey report on Cancer Angiogenesis Inhibitors   is composed of inspection of different countries around the world based on certain market indicators such as new market segment, converting non-customer into a customer, selling a new product to an existing customer. Countries with a wide range of economic systems mean sustainable advantage which will protect them from economic downturns as well as competitors. Countries in the Asia-Pacific region also show a great signal of development due to the population figure in this part of the world which establishes an efficient marketing environment. The survey report on Cancer Angiogenesis Inhibitors   also uses numerous graphical tools and techniques for easy and better understanding to the readers.

<strong>Customization of the report: </strong> Qualitative research uses various techniques to provide subjective data. We provide customized reports at a discounted price.

<strong>Top Listed Companies in the Cancer Angiogenesis Inhibitors  Market Include</strong>

Intas Pharmaceuticals,Five Prime Therapeutics,Mabtech,Kyowa Hakko Kirin,Genentech,Levolta Pharmaceuticals,Genexine,Neumedicines,Marsala Biotech,Fuji Film Kyowa Kirin Biologics,Hetero Drugs,ImClone Systems,Novartis

<strong>Reasons to buy this report:</strong> This report on Cancer Angiogenesis Inhibitors   helps in understanding the major key product segments. This report on Cancer Angiogenesis Inhibitors   throws light on the dynamics of the market such as drivers, restraints, trends, and opportunities. It offers the regional analysis of Cancer Angiogenesis Inhibitors   Market along with business profiles of several stakeholders in the research market. It offers massive data about trending factors that will influence the progress of the Cancer Angiogenesis Inhibitors   Market. It offers an in-depth analysis of the changing competitive scenario in the Cancer Angiogenesis Inhibitors   market of the research industry.

<strong>Request for Customization @ <a href=https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=81109>https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=81109</a></strong>

<strong>Benefits:</strong> 1. Discount offer. 2. Excel datasheet. 3. Well-evaluated data. 4. We provide service in 35+ countries. 5. Leading market research.

<strong>Services:</strong> 1. 24 hours help assistance. 2. Doubt clearance help provided. 3. Quarterly updated report. 4.Up-to-date report. 5. Expert advice.

<strong>Frequently Asked Questions?</strong> Q1. What is the total market value of the Cancer Angiogenesis Inhibitors  market report? Q2. What would be the forecast period in the Cancer Angiogenesis Inhibitors  market report? Q3. What is the base year considered in the Cancer Angiogenesis Inhibitors   market report? Q4. Which are the top companies hold the market share in the Cancer Angiogenesis Inhibitors   market ? Q5. Which is expected to be the fastest growing segment in the Cancer Angiogenesis Inhibitors   market? Q6. Which market holds the maximum market share of the Cancer Angiogenesis Inhibitors   market ? Q7. How the company profile has been selected? Q8. What will be the market value of the Cancer Angiogenesis Inhibitors  market in 2028?

<strong>Full Report Summary of Cancer Angiogenesis Inhibitors  Market @ <a href=https://www.statistifymarketresearch.com/cancer-angiogenesis-inhibitors-market>https://www.statistifymarketresearch.com/cancer-angiogenesis-inhibitors-market</a></strong>

<strong>About Statistify Market Research</strong> Statistify Market Research gives worldwide ventures just as medium and independent companies with unparalleled nature of Market Research Reports and Business Intelligence Solutions. We have a focused visible to give business experiences and counseling to help its customers to settle on vital business choices and accomplish feasible development in their separate market area. We are in expert corporate relations with different organizations and this encourages us in uncovering market information that causes us to produce exact research information tables and affirms the most extreme precision in our market determining..

<strong>Company Name - Statistify Market Research</strong> Office Address - 156, Sector 9 Vasundhra Aptts Rohini, New Delhi 110085 IN Telephone Numbers - (+44) 162-237-1047 (+44) 162-237-1047 Email ID - <a href="mailto:sales@statistifymarketresearch.com"><strong>sales@statistifymarketresearch.com</strong></a> Contact Us – <a href="https://www.statistifymarketresearch.com/contact-us/"><strong>https://www.statistifymarketresearch.com/contact-us/</strong></a>

[thesunshinereporter]

Adult Growth Hormone Deficiency Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working | Companies-OPKO Health, Genexine, Ascendis Pharma

http://dlvr.it/Smf9t5

[market-insider]

Human Growth Hormone Market Size Worth $8.5 Billion By 2027

The global human growth hormone market size is expected to reach a value of USD xx billion by 2027, registering a CAGR of xx% over the forecast period, according to a new report by Grand View Research, Inc. Introduction of novel therapies, increasing R&D activities, and the rising awareness for the diagnosis and treatment of growth hormone (GH) disorders are expected to drive the market over the forecast period.

Key players operating in the market are involved in extensive R&D activities for the development of novel GH therapies to strengthen their position in the market. For instance, in October 2019, VISEN Pharmaceuticals, a joint venture of Denmark-based Ascendis Pharma A/S, received approval from the China National Drug Administration (NMPA) for its new drug (IND) application to start Phase III clinical study of TransCon hGH. Furthermore, two South Korean companies, Genexine Inc. and Handok Inc. are conducting a Phase II clinical trial study on GX-H9, a recombinant human GH for the treatment of adult and pediatric GH deficiency.

For Sample Copy or More Details please visit link @: https://www.grandviewresearch.com/industry-analysis/human-growth-hormone-drugs-market

Furthermore, an increase in the number of regulatory approvals and the launch of novel HGH therapies are expected to fuel the market over the forecast period. For instance, in January 2018, Ferring Pharmaceuticals Inc., a Switzerland-based pharmaceutical company, received United States Food and Drug Administration (USFDA) approval for its new recombinant HGH, Zomacton (somatropin), indicated for the treatment of adult patients with GH deficiency.

Various government and private organizations have been undertaking initiatives and programs to spread awareness about GH deficiency and facilitate timely diagnosis and treatment. Nonprofit organizations such as the Human Growth Foundation are engaged in providing research support and spreading awareness about GH deficiency and its treatment. Such initiatives are expected to drive the demand for hGH treatment therapies.

[bidhuan]

Mulai Uji Klinik, Vaksin COVID-19 dari Kalbe Farma berteknologi DNA

Mulai Uji Klinik, Vaksin COVID-19 dari Kalbe Farma berteknologi DNA

Majalah Farmasetika – PT. Kalbe Farma bekerjasama dengan perusahaan asal Korea Selatan Genexine Inc, akan memulai uji klinik kandidat vaksin COVID-19 berbasis DNA di Indonesia (23/7/2020).

Berbeda dengan vaksin COVID-19 bernama CoronaVac hasil kerjasama antara Bio Farma dengan perusahaan biofarma Cina Sinovac, yang merupakan produk inaktivasi virus penyebab COVID-19, SARS-CoV-2.

Kalbe Farma…

[tayo4bus]

Joko widodo Amankan 100 Juta Vaksin Dari Inggris

Presiden Jokowi Berita 5 juta buruh Indonesia Hari Ini - Info Indonesia membeberkan update terkait vaksin corona yang sudah didapatkan Indonesia. Salah satunya vaksin dari AstraZeneca, Inggris.

“Tadi saya sudah mendapatkan laporan dari Pak Erick (Thohir) untuk Astrazeneca untuk bulan pertama di bulan April 2021 dan satu bulannya kita dapatkan kira-kira 11 juta,” ungkap Presiden Jokowi, Senin (19/10/2020).

Indonesia total telah mengamankan 100 juta dosis vaksin AstraZeneca. Di akhir Oktober,Berita 50 persen Indonesia Hari Ini - Info Indonesia Kemenkes akan membayar uang muka sebesar USD 250 juta.

“Dan totalnya dapat sekitar 100 juta, ini yang perlu kita ketahui bersama,” lanjut Presiden.

Jokowi mengingatkan, perencanaan program vaksinasi yang akan dimulai November 2020 dimatangkan. Selain AstraZeneca, sejauh ini kita sudah mendapatkan komitmen dari Sinovac, CanSino, dan Sinopharm dari China serta Genexine Korea Selatan.

“Jadi sekali lagi, di rapat ini juga tadi saya sampaikan yang kedua soal vaksin ini agar perencanaannya disiapkan Berita 500 kabupaten Indonesia Hari Ini - Info Indonesia betul agar kita tidak salah lagi dalam komunikasi publik yang ada,” tandasnya.

[sapanas]

Leukemia Therapeutics Market 2020: Company Profiles, Industry Segments, Size, Landscape, Demand and Business Trends

Market Research Future published a half-Cooked research report on “Global Leukemia Therapeutics Market Research Report, forecast to 2023” – Market Size, Share, Growth, Analysis, Regional Outlook, Scope, Stake, Progress, Trends.

Leukemia Therapeutics Market Overview

Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.

Read more news on: https://www.medgadget.com/2020/08/leukemia-therapeutics-market-to-grow-at-a-cagr-of-5-3-by-2023-covid-19-impact-analysis-top-comapnies-pfizer-inc-glaxosmithkline-plc-novartis-ag-bristol-myers-squibb-company-sanofi-s-a.html

Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).

The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.

On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.

Leukemia Therapeutics Market   - Segments      

The Leukemia Therapeutics Market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application          : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.

By Regions                 : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.

These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.

Leukemia Therapeutics Market   - Regional Analysis

North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.

Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.

Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.

The Asia Pacific region is emerging as a promising market for leukemia therapeutics. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.

Leukemia Therapeutics Market   - Competitive Analysis

The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.  

Leukemia Therapeutics Market Major Players:

Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Leukemia Therapeutics Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS).

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.

[aditi3019]

Global Leukemia Therapeutics Market 2019 - 2023: Emerging Technologies, Business Trends, Industry Segments, Global Segments, Landscape and Demand

Global Leukemia Therapeutics Market Report, Forecast Period 2023-2020. The Industry Research Report on Global Leukemia Therapeutics Market is based on Industry Size, Share, Trend and Growth.  

Global leukemia therapeutics market is growing pervasively and will continue to do so in the years to come due to the growing prevalence of leukemia. With considerable advancements in biotechnology, various innovative therapies have emerged, which drive the market growth excellently. The proven efficacies of these therapeutics in providing effective treatment for leukemia are allowing the market to accrue exponentially on the global platform. Well-spread awareness about leukemia therapeutics has spurred the growth of the market.

Rising numbers of medical science and biotechnology companies is a major driving force behind the growth of the market. Besides, the improving outlook for leukemia treatments that are controlling the spread of the diseases fosters the market growth phenomenally. According to Market Research Future (MRFR), the global leukemia therapeutics market had valued at USD 10.7 BN in 2017. The valuation is further projected to appreciate at 5.3% CAGR during the assessment period (2018-2023).  

The rapid adoption of leukemia therapeutics and increasing demand for effective treatment methods are driving the growth of the market. Additional factors, such as increasing numbers of R&D initiatives, clinical trials, and new approvals, are contributing to the growth of the market. Providers are collaborating with independent research centers and hospitals to bring novelties into therapies, which, as a result, are acting as major tailwinds for market growth.  

On the other hand, high costs and lack of awareness are projected to impede the growth of the leukemia therapeutics market. Nevertheless, increasing numbers of drug discoveries would support market growth throughout the assessment period. Rapid uptake of these therapies by medical professionals, as well as patients and increasing success rates, are driving the market.

Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/7425

Global Leukemia Therapeutics Market   - Segments       

The market is segmented into three main dynamics to widen the scope of understanding,

By Treatment Type: Chemotherapy (Alkylating Agents, Antimetabolites Antitumor Antibiotics, others), Biological Therapy, Targeted Therapy, Radiation Therapy, Stem Cell Transplant, and others.

By Application : Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, and others.  

By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.  

These therapeutics are used to treat a range of leukemia types, including acute myelogenous, acute lymphocytic, chronic lymphocytic, chronic myelogenous, and others. Among these, acute lymphocytic leukemia (ALL) is the largest segment in the market. The prevalence of this type of leukemia is the major reason behind the growth of the segment. Additionally, rising numbers of clinical trials and regulatory approvals push the segment growth. For instance, recently FDA approved blinatumomab, a bispecific T-cell engager (BiTE), as an effective method to treat patients with acute lymphocytic leukemia.

Global Leukemia Therapeutics Market   - Regional Analysis

North America dominates the global leukemia therapeutics market, heading with an increase in the prevalence of leukemia and the geriatric population. Besides, the presence of many well-established players, alongside innovative therapies is estimated to drive the leukemia therapeutics market in North America. The market growth is predominantly supported by the US market, which is growing due to the large patient pool and high healthcare expenditures.  

Moreover, technological advancements and well-spread awareness about the availability of leukemia therapeutics, support market growth. The North American leukemia therapeutics market is projected to retain its dominance in the global market throughout the review period.  

Europe stands second in the global leukemia therapeutics market. Increasing numbers of leukemia patients in the region drive the regional market predominantly. Furthermore, increased numbers of advanced treatment facilities, alongside the availability of skilled medical professionals and the government support for research & development, fosters regional market growth.

The Asia Pacific region is emerging as a promising market for leukemia therapeutics. Factors substantiating the market growth include increasing prevalence of leukemia and spreading awareness among people about the condition and availability of new treatment methods. China and India are proliferating markets for leukemia therapeutics, which contribute to the market growth in the region, majorly. The APAC leukemia therapeutics market is expected to grow phenomenally.

Global Leukemia Therapeutics Market   - Competitive Analysis

The leukemia therapeutics market appears fiercely competitive due to the presence of many well-established players. Significant investments are transpired in the field to bring innovations to the therapy and clinical trials. To gain a larger competitive share in the market, these players incorporate strategies such as partnerships, collaborations, mergers & acquisitions, expansions, and technology launch.  

Major Players:

Players leading the leukemia therapeutics market include Pfizer Inc. (US), Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Takeda Pharmaceutical Company Ltd (Japan), Amgen Inc (US), Hoffmann-La Roche AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), and Sanofi SA (France), among others. 

Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Industry/ Innovation/Related News:

March 07, 2020 ---- Quantbot Technologies LP (the US), an SEC-registered investment adviser, announced, purchasing a new stake in a US-based biopharmaceutical company - TG Therapeutics Inc. The purchased 2,599 shares valued at approximately USD 28,000. TG Therapeutics is involved in developing & delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). 

January 20, 2020 ---- CoImmune, a joint venture set up by SCM Life Science and Genexine in the US, announced the Formula Pharmaceuticals (Italy), a leader in the immunotherapy platform. Through this acquisition, CoImmune gets the rights to all tangible and intangible assets of Formula, expanding the company's pipeline with two additional drug candidates. Formula's Cytokine-Induced Killer Cell (CAR-CIK) is an acute lymphocytic leukemia drug, and CMN-001 is an advanced renal cancer drug.